scispace - formally typeset
Journal ArticleDOI

EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome

Reads0
Chats0
TLDR
The EULAR SS Patient Reported Index is a very simple index designed to measure patients' symptoms in primary SS and has good construct validity and is well correlated with SSI and PROFAD.
Abstract
Objectives To develop a score for assessment of patients9 symptoms in primary Sjogren9s syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS, in studies developing the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI). It was suspected that a single 0–10 numerical scale for each domain was sufficient to assess these symptoms. These four scales were gathered to form the ESSPRI. 230 patients, from 12 countries completed the ESSPRI, SSI and PROFAD questionnaires and a 0–10 patient global assessment (PGA). Correlations between each symptom and PGA were obtained. Multiple regression modelling, using PGA as ‘gold standard’ was used to select domains and estimate their weights. Results PGA had good correlation with dryness, limb pain, fatigue and mental fatigue (r=0.49–0.59, all p Conclusion ESSPRI is a very simple index designed to measure patients9 symptoms in primary SS. It has good construct validity and is well correlated with SSI and PROFAD. ESSPRI should now be validated for use as an outcome measure in clinical trials.

read more

Citations
More filters
Journal ArticleDOI

Primary Sjögren’s Syndrome

TL;DR: In the absence of trials involving patients with primary Sjögren's syndrome, severe organ manifestations are treated with immunosuppressive agents (including prednisone, methotrexate, mycophenolate sodium, azathioprine, and cyclophosphamide), in accordance with guidelines for systemic lupus erythematosus and other connective‐tissue diseases.
Journal ArticleDOI

Sjögren syndrome

TL;DR: Knowledge of SjS has progressed substantially, but this disease is still characterized by sicca symptoms, the systemic involvement of disease, lymphocytic infiltration to exocrine glands, the presence of anti-Ro/SSA and anti-La/SSB autoantibodies and the increased risk of lymphoma in patients with SJS.
Journal ArticleDOI

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

TL;DR: Encouraging results justify future randomised controlled trials of belimumab in a selected target population of pSS patients most likely to benefit from treatment.
References
More filters
Journal ArticleDOI

Modified disease activity scores that include twenty-eight-joint counts : development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

TL;DR: The Modified DAS that included 28-joint counts were able to discriminate between high and low disease activity (as indicated by clinical decisions of rheumatologists) and are as valid as disease activity scores that include more comprehensive joint counts.
Journal ArticleDOI

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

TL;DR: These classification criteria for Sjögren's syndrome have been re-examined by consensus group members, who have introduced some modifications, more clearly defined the rules for classifying patients with primary or secondary SS, and provided more precise exclusion criteria.
Journal ArticleDOI

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

TL;DR: Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS and MALT/primary SS and the high incidence of HACAs and associated side effects observed in this study needs further evaluation.
Journal ArticleDOI

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

TL;DR: Rituximab treatment is an effective and safe treatment strategy for patients with primary Sjögren's syndrome and significant improvements were found in comparison with baseline values.
Related Papers (5)